Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPHNYSE:CNANYSEAMERICAN:GLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$25.82-2.3%$24.67$22.64▼$53.96$1.22B0.77489,749 shs402,402 shsCNACNA Financial$45.64-1.0%$47.67$43.11▼$52.36$12.35B0.53325,809 shs335,197 shsGLOClough Global Opportunities Fund$5.28-0.4%$5.02$4.32▼$5.60N/AN/A161,775 shs87,509 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals0.00%-0.65%+6.17%-3.15%-36.17%CNACNA Financial0.00%-3.21%-6.36%-6.95%+3.85%GLOClough Global Opportunities Fund0.00%-0.56%+1.34%+6.67%+10.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPHAmphastar Pharmaceuticals4.2391 of 5 stars3.11.00.03.72.84.21.3CNACNA Financial4.4232 of 5 stars1.85.04.20.63.62.51.9GLOClough Global Opportunities FundN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.25Hold$32.3325.23% UpsideCNACNA Financial 1.50Reduce$50.5010.65% UpsideGLOClough Global Opportunities Fund 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RUR, CNA, GLO, and AMPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025AMPHAmphastar PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$45.00 ➝ $30.005/8/2025AMPHAmphastar PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $35.004/10/2025AMPHAmphastar PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/21/2025AMPHAmphastar PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $32.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$730.66M1.67$3.60 per share7.17$13.35 per share1.93CNACNA Financial$14.18B0.87$4.01 per share11.37$38.81 per share1.18GLOClough Global Opportunities FundN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$137.54M$2.768.617.852.1921.80%26.44%11.89%8/6/2025 (Estimated)CNACNA Financial$959M$3.2812.979.639.236.72%12.90%1.99%8/4/2025 (Estimated)GLOClough Global Opportunities FundN/AN/A0.00∞N/AN/AN/AN/AN/ALatest RUR, CNA, GLO, and AMPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025CNACNA Financial$1.16$1.03-$0.13$1.00$3.68 billion$3.63 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/ACNACNA Financial$1.844.03%N/A56.10%9 YearsGLOClough Global Opportunities Fund$1.2223.11%N/AN/AN/ALatest RUR, CNA, GLO, and AMPH DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/9/2025GLOClough Global Opportunities Fundmonthly$0.050113.4%6/17/20256/17/20256/30/20254/8/2025GLOClough Global Opportunities Fundmonthly$0.050113.4%6/17/20256/17/20256/30/20255/6/2025CNACNA Financialquarterly$0.463.8%5/19/20255/19/20256/5/20255/16/2025GLOClough Global Opportunities Fund$0.050111.54%5/19/20255/20/20255/30/20254/16/2025GLOClough Global Opportunities Fund$0.050112.85%4/17/20254/18/20254/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.823.432.61CNACNA Financial0.280.280.28GLOClough Global Opportunities FundN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%CNACNA Financial98.45%GLOClough Global Opportunities FundN/AInsider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals27.50%CNACNA Financial0.30%GLOClough Global Opportunities FundN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,62047.14 million35.05 millionOptionableCNACNA Financial6,100270.62 million270.05 millionOptionableGLOClough Global Opportunities FundN/AN/AN/ANot OptionableRUR, CNA, GLO, and AMPH HeadlinesRecent News About These CompaniesClough Closed-end Funds Announce Renewal of Share Repurchase ProgramsJune 13 at 8:30 AM | finance.yahoo.comWhen Diversification Fails: This 11.3% Dividend Has A Huge Hidden CostJune 10, 2025 | forbes.comClough Global Opportunities Fund Section 19(a) Notice | GLO Stock NewsApril 30, 2025 | gurufocus.comClough Global Opportunities Fund Section 19(a) NoticeApril 30, 2025 | gurufocus.comClough Global Opportunities Fund Section 19(a) NoticeApril 30, 2025 | accessnewswire.comClough Global Opportunities Fund Declares Monthly Cash Distributions for April, May and June ...April 7, 2025 | gurufocus.comGLO: Not Impressed With This Global FundApril 1, 2025 | seekingalpha.comClough Global Opportunities Fund Section 19(a) NoticeMarch 31, 2025 | gurufocus.comClough Global Opportunities Fund Section 19(a) NoticeMarch 31, 2025 | accessnewswire.comClough Global Opportunities Fund Section 19(a) NoticeFebruary 28, 2025 | accessnewswire.comRiverNorth Capital Management, LLC Increases Stake in Clough Global Opportunities FundFebruary 14, 2025 | gurufocus.comClough Global Opportunities Fund Section 19(a) NoticeJanuary 31, 2025 | accessnewswire.comClough Global Opportunities Fund Section 19(a) NoticeDecember 30, 2024 | accesswire.comClough Global Opportunities Fund Section 19(a) NoticeNovember 29, 2024 | accesswire.comGLO: The Yield Is Nice, But Not A Fan Of The PortfolioOctober 27, 2024 | seekingalpha.comClough Global Opportunities Fund.October 23, 2024 | 247wallst.comCBRE Investment Management Taps New Leaders for U.S. & Global Funds StrategyOctober 11, 2024 | commercialobserver.comTrend Tracker for (GLO)October 7, 2024 | news.stocktradersdaily.comClough Global Opportunities Fund Declares Monthly Cash Distributions for October, November and December of $0.0480 Per ShareOctober 7, 2024 | finance.yahoo.comWant $1,200 in Annual Passive Income? Invest $1,200 in Each Of These 9 StocksOctober 2, 2024 | 247wallst.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueArcher Rebuts Short Seller, Points to Strong Q1 & Global MomentumBy Jeffrey Neal Johnson | May 22, 2025View Archer Rebuts Short Seller, Points to Strong Q1 & Global MomentumASML’s AI Edge: How Its EUV Tech Is Creating a New MonopolyBy Jeffrey Neal Johnson | June 10, 2025View ASML’s AI Edge: How Its EUV Tech Is Creating a New MonopolyJoby's Saudi MoU: Strong Initial Reaction Meets Market DynamicsBy Jeffrey Neal Johnson | June 4, 2025View Joby's Saudi MoU: Strong Initial Reaction Meets Market DynamicsRUR, CNA, GLO, and AMPH Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$25.82 -0.62 (-2.34%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$25.83 +0.01 (+0.04%) As of 06/13/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.CNA Financial NYSE:CNA$45.64 -0.45 (-0.98%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$45.66 +0.02 (+0.04%) As of 06/13/2025 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CNA Financial Corporation provides commercial property and casualty insurance products in the United States and internationally. It operates through Specialty, Commercial, International, Life & Group, and Corporate & Other segments. The company offers professional liability coverages and risk management services to various professional firms, including architects, real estate agents, and accounting and law firms; directors and officers, employment practices, fiduciary, and fidelity and cyber coverages to small and mid-size firms, public and privately held firms, and not-for-profit organizations; professional and general liability, as well as associated casualty coverages for healthcare industry; surety and fidelity bonds; and warranty and alternative risks products. It also provides property, marine, boiler, and machinery coverage insurance products; casualty insurance products comprising workers' compensation, general and product liability, commercial auto, umbrella, and excess and surplus coverages; specialized loss-sensitive insurance programs and total risk management services; and run-off long term care policies. The company was founded in 1853 and is based in Chicago, Illinois. CNA Financial Corporation operates as a subsidiary of Loews Corporation.Clough Global Opportunities Fund NYSEAMERICAN:GLO$5.28 -0.02 (-0.38%) Closing price 06/13/2025 04:10 PM EasternExtended Trading$5.14 -0.14 (-2.65%) As of 06/13/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clough Global Opportunities Fund is a closed ended balanced mutual fund launched and managed by Clough Capital Partners L.P. It invests in public equity and fixed income markets across the globe. The fund invests in securities of companies operating across diversified sectors. For its fixed income portion, the fund invests in both investment grade and non-investment grade issues. It employs a combination of fundamental and quantitative analysis with bottom-up stock picking approach to create its portfolio. Clough Global Opportunities Fund was formed on January 12, 2006 and is domiciled in the United States. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
